Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese

International Journal of Cancer

Volumn 130, Issue 3, 2012, Pages 671-676

  Dai, Juncheng ^a   Hu, Zhibin ^a   Dong, Jing ^a   Xu, Lin ^b   Pan, Shiyang ^c   Jiang, Yue ^a   Jin, Guangfu ^a   Chen, Yijiang ^c   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

immune genes; molecular epidemiology; NSCLC; polymorphism; survival

Indexed keywords

5' UNTRANSLATED REGION; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; GENE; GENE LOCUS; GENOTYPE; HOST IMMUNE GENE; HUMAN; IL5R GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SINGLE NUCLEOTIDE POLYMORPHISM; TLR1 GENE; TLR3 GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CHINA; GENOTYPE; HUMANS; IMMUNITY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; ROC CURVE;

EID: 82255175202     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26067     Document Type: Article

References (27)

1. Schetter AJ, Heegaard NH, Harris CC,. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49.
2. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45. (Pubitemid 32173595)
3. Takeda K, Kaisho T, Akira S,. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76. (Pubitemid 37174535)
4. Iwasaki A, Medzhitov R,. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95. (Pubitemid 41057715)
5. Aderem A, Ulevitch RJ,. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
6. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G,. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-81. (Pubitemid 28225722)
7. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Kloss M, Gocht D, Potthoff B, Tzvetkov M, Brockmoller J, Loffler M, Pfreundschuh M, et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res 2008; 14: 3777-84.
8. Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, Pfreundschuh M, Trumper L, Kube D,. Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 2009; 20: 1548-54.
9. Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008; 112: 2694-702.
10. Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007; 109: 5439-46. (Pubitemid 46890567)
11. Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS,. Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis. Blood 2008; 111: 1625-33. (Pubitemid 351213454)
12. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L,. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005; 16: 253-60. (Pubitemid 350056539)
13. Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, Terachi T, Tachibana M, Matsushiro H, Habuchi T, Kakehi Y, Ogawa O,. Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res 2002; 8: 2620-5. (Pubitemid 34856349)
14. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R,. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007; 25: 845-51. (Pubitemid 350002885)
15. Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, Huang X, Shen H,. A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16: 1236-44.
16. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-44. (Pubitemid 30422619)
17. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-708. (Pubitemid 34556153)
18. Trinchieri G,. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46. (Pubitemid 37328691)
19. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V,. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9: 650-7. (Pubitemid 351712635)
20. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3. (Pubitemid 44871953)
21. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90. (Pubitemid 46175676)
22. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 830-2. (Pubitemid 47014496)
23. Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Davies G, Anderson NH, Gillett PM, McGrogan P, Hassan K, Weaver L, Bisset WM, et al. IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut 2007; 56: 1173-4. (Pubitemid 47123258)
24. Janssens S, Beyaert R,. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003; 16: 637-46. (Pubitemid 37296552)
25. Spitzer JH, Visintin A, Mazzoni A, Kennedy MN, Segal DM,. Toll-like receptor 1 inhibits Toll-like receptor 4 signaling in endothelial cells. Eur J Immunol 2002; 32: 1182-7. (Pubitemid 34428836)
26. Hajjar AM, O'Mahony DS, Ozinsky A, Underhill DM, Aderem A, Klebanoff SJ, Wilson CB,. Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001; 166: 15-9. (Pubitemid 32038411)
27. Pahl HL, Scheibe RJ, Zhang DE, Chen HM, Galson DL, Maki RA, Tenen DG,. The proto-oncogene PU. 1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993; 268: 5014-20. (Pubitemid 23081625)